Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
* Revenue of US$51.7 million in the second quarter of 2022 * Loss from operations of US$(17.9) million and adjusted EBITDA[1] of US$6.5 million in the same period * Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue ...
Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device
- Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally. - The test utilises a CE-certified blood collection device, which is a proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process....
Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong
- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the onl...
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"
LONDON and HONG KONG, June 6, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. The Company recorded strong opera...
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer
HANGZHOU, China and HONG KONG, May 23, 2022 /PRNewswire/ -- New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, "Prenetics") has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the "First Colorectal Cancer Screening Test approved inChina", in Hong K...
